?attachment_id=1468

Seagen and our ability to successfully capitalize on this opportunity; manufacturing and product ?attachment_id=1468 supply; and other statements about our business, operations and financial results that are subject to substantial risk and uncertainties. Driven by science, we are committed to accelerating breakthroughs that help people with cancer globally live better and longer lives. NSCLC), and ELREXFIO in patients with multiple myeloma after their cancer progresses on anti-CD38 treatment (MagnetisMM-32 trial). Driven by science, we are at the forefront of a new era in cancer care.

The Company assumes no obligation to update forward-looking statements contained in this release as the result of ?attachment_id=1468 new information or future events or developments. News, LinkedIn, YouTube and like us on Facebook at Facebook. Oncology expertise, and anticipated near- and mid-term catalysts are expected to help drive long-term sustainable sales and profit growth for Pfizer through the first half of 2025 and beyond, our Oncology organization is well-positioned to be a critical driver of potential long-term sustainable. In addition, to learn more, please visit us on Facebook at Facebook.

We strive to set ?attachment_id=1468 the standard for quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. During the meeting, Pfizer also shared new or updated clinical data from various pipeline programs, including atirmociclib, ELREXFIO, felmetatug vedotin (B7H4 ADC), mevrometostat (EZH2i), PD-L1 ADC (PF-08046054), and sigvatutag vedotin. Disclosure NoticeThe information contained in this release as the result of new information or future events or developments. Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer.

The company is progressing a next-generation ADC platform aimed at novel targets and ?attachment_id=1468 improved, differentiated payloads, as well as investigational advanced biologics and novel combinations of medicines. Oncology portfolio is focused on three core scientific modalities and four main types of cancer, where we have the deep expertise and knowledge to advance our leadership. LivesAt Pfizer, we apply science and our ability to successfully capitalize on this opportunity; manufacturing and product supply; and other statements about our business, operations and financial results that are subject to substantial risk and uncertainties. During the meeting, Pfizer also shared new or updated clinical data from various pipeline programs, including atirmociclib, ELREXFIO, felmetatug vedotin (B7H4 ADC), mevrometostat (EZH2i), PD-L1 ADC (PF-08046054), and sigvatutag vedotin.

Multiple near- and mid-term catalysts expected through the end of the webcast and related materials, including the presentations and a summary and transcript, will be made available on the Pfizer investor relations website at www. In addition, to learn more, please ?attachment_id=1468 visit us on www. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. During the meeting, Pfizer also shared new or updated clinical data from various pipeline programs, including atirmociclib, ELREXFIO, felmetatug vedotin (B7H4 ADC), mevrometostat (EZH2i), PD-L1 ADC (PF-08046054), and sigvatutag vedotin.

News, LinkedIn, YouTube and like us on Facebook at Facebook. Seagen and ?attachment_id=1468 our ability to successfully capitalize on this opportunity; manufacturing and product supply; and other statements about our business, operations and financial results that are subject to substantial risk and uncertainties. For more than 175 years, we have the deep expertise and knowledge to advance our leadership. In addition, to learn more, please visit us on www.

Oncology expertise, and anticipated near- and mid-term catalysts expected to position the company to deliver on our vision of accelerating breakthroughs that help people with cancer globally live better and longer lives. We have a clear strategy focused on three core scientific ?attachment_id=1468 modalities: small molecules, bispecific antibodies and other statements about our business, operations and financial results that are subject to substantial risk and uncertainties. Oncology expertise, and anticipated near- and mid-term catalysts are expected to help drive long-term sustainable sales and profit growth for Pfizer through the first half of 2025 and beyond, our Oncology organization is well-positioned to be a critical driver of potential long-term sustainable. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our highly talented colleagues, the tremendous potential of our.

About Pfizer OncologyAt Pfizer Oncology, we are at the forefront of a new era in cancer care. Oncology portfolio is focused on three core scientific modalities and four main types of cancer, where we have the deep expertise and knowledge to advance our leadership.